Novartis

QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM 1 & 2 studies showed NVA237 provided significant and clinically meaningful improvements in lung function in moderate-to-severe COPD patients[8],[9] In … Read the full press release →

New research led by the University of Warwick shows newly diagnosed advanced prostate cancer patients who received the chemotherapy drug docetaxel with standard hormone therapy lived ten months longer on average, compared to those who received standard therapy alone. COVENTRY, … Read the full press release →

New analysis will confirm high efficacy of Gilenya® in achieving ‘no evidence of disease activity’ (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding brain shrinkage to an existing assessment tool enhances ability to predict disability progression in … Read the full press release →

New hub based in Rockville, MD expands GSK’s global vaccines R&D footprint London and Philadelphia, 6-4-2015 — /EuropaWire/ — GSK announced today it is further strengthening and expanding its vaccines presence in the US by establishing a new global centre … Read the full press release →

Jakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea PV is a rare blood cancer associated with an overproduction of blood cells that can lead to serious cardiovascular complications … Read the full press release →

Approximately 400 mothers and newborns die in Ethiopia each day1,2partly due to health workers’ limited knowledge in the area of obstetrics Enhancing medical knowledge and skills of health workers helps reduce maternal and newborn mortality Sandoz is committed to increasing … Read the full press release →

In 2014, ABB filed more patent applications in Europe than any other company in Switzerland, for the second consecutive year Zurich, Switzerland, 27-02-2015 — /EuropaWire/ — ABB, the leading power and automation technology group, registered more patent applications with the … Read the full press release →

Decision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months Filing is based on results from the landmark PARADIGM-HF study[1] Nearly six million people live with heart failure in … Read the full press release →

With today’s approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero’s two-dose regimen offers a flexible dosing schedule, with the first and second doses administered at least … Read the full press release →

Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (ruxolitinib) significantly improved hematocrit levels and reduced spleen size, key measures of disease control[2] … Read the full press release →